NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 176 filers reported holding NEVRO CORP in Q2 2016. The put-call ratio across all filers is 0.80 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $6,000 | -25.0% | 77 | 0.0% | 0.00% | – |
| Q3 2016 | $8,000 | -81.4% | 77 | -86.7% | 0.00% | -100.0% |
| Q2 2016 | $43,000 | +34.4% | 577 | 0.0% | 0.00% | +100.0% |
| Q1 2016 | $32,000 | -5.9% | 577 | +15.4% | 0.00% | -50.0% |
| Q4 2015 | $34,000 | +47.8% | 500 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $23,000 | -14.8% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $27,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |